Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status

The aim of this study was to assess whether combining multimodal magnetic resonance imaging (MRI) with the determination of the 1p/19q codeletion status could improve the ability to predict anaplastic transformation in low-grade oligodendrogliomas. Twenty patients with grade II oligodendrogliomas were followed-up using multimodal MR [proton MR spectroscopy (MRS), perfusion, and conventional MR imaging]. All patients diagnoses were histologically proven, and 1p/19q codeletion status was analyzed for all patients. Median follow-up was 30.5 ± 11.4 months. Anaplastic transformation was observed in six patients. The only MRI feature that was associated with anaplastic transformation was an elevation of the choline/creatine ratio >2.4 which was observed in 4 out of 6 patients with anaplastic transformation versus 1 out of 14 patients without anaplastic transformation. In patients without 1p/19q codeletion, an elevation of the choline/creatine ratio >2.4 was associated with the occurrence of anaplastic transformation in all cases (4 out of 4 patients), with a mean time of 12 months. In contrast, in patients with a 1p/19q codeletion, no anaplastic transformation was observed in the patient who had an elevation of >2.4 of the choline/creatine ratio and two patients demonstrated an anaplastic transformation without any elevation of this ratio.Prospective validation in a larger series is needed, yet the present study suggests that combining data from in vivo proton MRS and genetic analysis could be a promising strategy to predict time to anaplastic transformation at the individual level in patients with low-grade oligodendrogliomas and may help deciding when chemotherapy and/or radiotherapy should be initiated in these tumors.

[1]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[2]  Philippe Cornu,et al.  Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. , 2002, International journal of radiation oncology, biology, physics.

[3]  J. Hunter,et al.  Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings , 2002, Neurology.

[4]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Williams,et al.  Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells , 2006, Acta Neuropathologica.

[6]  B. Scheithauer,et al.  Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[8]  F. Jolesz,et al.  Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance , 2005, Cancer.

[9]  R. Guillevin,et al.  Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. , 2013, Neuro-oncology.

[10]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[11]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. von Deimling,et al.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.

[13]  J. Guyotat,et al.  Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors , 2006, Neuroradiology.

[14]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Luc Taillandier,et al.  Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates. , 2012, Neurosurgery.

[16]  R. Guillevin,et al.  Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas , 2012, Journal of magnetic resonance imaging : JMRI.

[17]  A. Waldman,et al.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? , 2008, Radiology.

[18]  D J Jenden,et al.  In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.

[19]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[20]  G. Reifenberger,et al.  Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? , 2011, Clinical Cancer Research.

[21]  H Duffau,et al.  Temozolomide for low-grade gliomas , 2007, Neurology.

[22]  E. Shaw,et al.  Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. , 2005, International journal of radiation oncology, biology, physics.

[23]  H Duffau,et al.  Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985–96) and with (1996–2003) functional mapping in the same institution , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[25]  Mitchel S Berger,et al.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas. , 2008, Journal of neurosurgery.

[26]  A. Kaye,et al.  Low grade glial neoplasms , 2003, Journal of Clinical Neuroscience.

[27]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[28]  B. Nahed,et al.  Low-grade gliomas. , 2014, The oncologist.

[29]  Mitchel S Berger,et al.  Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. , 2007, Journal of neurosurgery.

[30]  K. Hoang-Xuan,et al.  NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas , 2009, PloS one.

[31]  L. Douw,et al.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up , 2009, The Lancet Neurology.

[32]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[33]  C. Meyer,et al.  Impact of perfusion map analysis on early survival prediction accuracy in glioma patients. , 2013, Translational oncology.

[34]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Henry Brem,et al.  EXTENT OF SURGICAL RESECTION IS INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITH HEMISPHERIC INFILTRATING LOW‐GRADE GLIOMAS , 2008, Neurosurgery.

[36]  Martin Klein,et al.  Cognitive deficits in adult patients with brain tumours , 2004, The Lancet Neurology.

[37]  G. Krol,et al.  Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.

[38]  J. Jolles,et al.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.

[39]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  R. Guillevin,et al.  Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy , 2011, British Journal of Cancer.

[41]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[42]  Laurence Abeloos,et al.  Prise en charge des gliomes de bas grade : série rétrospective de 201 patients , 2007 .

[43]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Gereon R Fink,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma , 2013, The Journal of Nuclear Medicine.

[45]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[46]  W. Schlote,et al.  Preoperative Proton-MR Spectroscopy of Gliomas – Correlation with Quantitative Nuclear Morphology in Surgical Specimen , 2003, Journal of Neuro-Oncology.

[47]  J. Honnorat,et al.  Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas , 2010, Journal of Neuro-Oncology.

[48]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.